Biotech Values

[rfj1862]

ARAV

Well as much as I like to keep my portfolio conservative (outside of VKTX and TGTX) I decided to take a flyer on ARAV as a "biotech value."

Seems to me that they are very substantially undervalued with a late-phase unique biologic for use in ovarian, cc-renal, and pancreatic primarily in combination with chemo, TK inhibitors, or nivo. Phase 3 data "mid-2023" and BLA Q4 2023 if successful.

Current market cap is ~128M at $2.15/share -- looking at the data including the multiple fast track designation I would think that it would be worth multiples of this?

I am mostly here so you can talk me out of this